Teva
Campaign TargetTeva is headquartered in Israel and is one of the world's biggest generic drug manufacturers. Every time institutions buy from Teva, it strengthens a key pillar of the Israeli economy.
Take Action
Apply pressure where it matters. Use these tools and personalise your message with evidence from this page.
- Contact Corporate LeadershipPre-filled letter templates for healthcare industry pressure
- Report New IntelligenceSubmit evidence of contracts, partnerships, or complicity
- Share This ProfileShare on LinkedIn to reach healthcare professionals
- Strategic AnalysisIn-depth analysis and engagement strategy
Before taking action, review our Code of Conduct for professional standards and ethical guidelines.
Help Us Hold Teva Accountable
Your skills and knowledge can strengthen this campaign. Join our volunteer research team or share insider information securely.
Leverage Your Expertise
Do you work in this sector? We need professionals who understand procurement cycles, regulatory compliance, and corporate governance. Don't just boycott - lead!
Decision-Maker Directory
Key individuals with influence over corporate partnerships and procurement decisions. Direct your correspondence to the most relevant role.
Material Risk Framing
Frame your message around business risks. These talking points resonate with corporate stakeholders and institutional investors.
Procurement from a company contributing 10% of industrial GDP to a state facing ICJ genocide proceedings creates due diligence obligations for institutional buyers under emerging human rights legislation
Dual-listed NYSE and TASE with significant debt creates sensitivity to institutional divestment campaigns; ESG-focused investors increasingly scrutinising exposure to companies funding states implicated in war crimes
Healthcare institutions face reputational risk sourcing from Israel's largest company while it publicly supports IDF operations; growing 'No Teva' campaigns across European healthcare systems
Generic pharmaceutical market is highly competitive - equivalent alternatives from Sandoz, Accord, Viatris, and Dr. Reddy's exist for most Teva products, enabling straightforward supplier substitution without compromising patient care
Product Alternatives
Ethical replacements tagged by what matters to you: cost, quality, ethics, sustainability, or local sourcing. Make the switch today.
Patient Safety First!
Do not stop or change prescribed medication without consulting your doctor or pharmacist.
Anticoagulants
Blood thinning medications - alternatives to Teva generic anticoagulants
Alternative to Teva Apixaban. NHS actively supports generic substitution for cost savings of over 90% versus branded Eliquis.
Oncology
Cancer treatment medications
Alternative to Teva Lenalidomide for multiple myeloma. Significant cost reduction versus branded Revlimid.
Multiple Sclerosis
MS treatment alternatives
Respiratory/Asthma
Inhaler and respiratory medication alternatives
Primary alternative to Teva Qvar inhalers. Equipotent extra-fine particle formulation, directly comparable to Qvar.
Standard-particle beclometasone option. Different particle size to Qvar - discuss suitability with your doctor or pharmacist.
Migraine
Migraine prevention and treatment alternatives
Ophthalmology
Eye treatment biosimilars
Antibiotics
Antibiotic alternatives
OTC & Consumer Products
Over-the-counter and pharmacy medicines
Alternatives to Teva Motusol gel. Identical active ingredient, often cheaper.
Alternative to Teva Sildenafil. Multiple generic suppliers available.
Comparison Legend
Strategic Analysis
In-depth assessment of the company's position, vulnerabilities, and recommended approaches for effective engagement.
High severity, high vulnerability — campaigns with the best chance of making an impact
Learn about our methodology — companies are categorised based on severity (harm potential) vs strategic vulnerability (campaign leverage).
Why do these scores change?
Unlike static boycott lists, our targeting model is dynamic. This company's position on the matrix is re-evaluated continually as we verify new contracts, divestments, or policy changes. Your reporting directly impacts this score.
Teva operates a dualistic strategy in the UK market: leveraging its position as one of the world's largest generic manufacturers to fund innovative specialty medicines like Ajovy (migraine) and biosimilars like Ongavia. Israel's largest company by revenue, Teva's economic contribution through employment and tax revenue is substantial.
UK Market Reality
For Teva's generics portfolio (apixaban, rivaroxaban, lenalidomide), the UK market features intense price competition with multiple alternative suppliers. Generic substitution is straightforward and cost-saving. For specialty medicines like Ajovy, therapeutic alternatives exist within NICE-approved drug classes. The NHS actively encourages biosimilar adoption over originators and generic substitution where clinically appropriate.
Key Leverage Points
- Institutional Procurement: NHS trusts and ICBs make procurement decisions subject to supplier review - focus engagement here rather than individual patients
- Generic Market Competition: Teva competes with Sandoz, Accord, Mylan (Viatris), and others - alternatives exist for most products
- Financial Vulnerability: Recent restructuring and significant debt creates sensitivity to reputational pressure
- Israeli Economy Significance: As Israel's largest company, Teva's performance significantly impacts the national economy
Engagement Strategy
Campaigns should target institutional purchasing decisions rather than individual prescriptions. Engage hospital pharmacy leads and procurement officials on supplier diversification. For generic products, viable alternatives from non-Israeli suppliers exist across most therapeutic categories. Patient access to necessary medications must be preserved - the focus should be on demonstrating that ethical procurement policies are compatible with clinical excellence and cost-effectiveness.
Evidence & Sources
Verified sources including NGO reports, regulatory filings, and primary documents. Use these to substantiate your correspondence.
Healthcare Workers for Palestine launched worldwide 'No Teva' campaign. Endorsed by BDS Movement. Pressure mounting on governments and pharmacies across Ireland, Belgium, Italy to replace Teva products
Open sourceDocuments Teva's support for IDF including medical supplies donations, participation in 'Adopt-a-Battalion' program, and 1.5 tons of equipment collected through employee collection points at 5 Israeli sites
Open sourceIndependent research commissioned by Norwegian hospital procurement agency examining Teva's activities and connections to Israeli military operations
Open sourceTeva agreed to pay $750 million to Israel Tax Authority resolving disputes for 2008-2020. Additionally committed to 5-7% of future dividends/repurchases as corporate tax, up to $500 million maximum
Open sourceOver 30 protesters blocked Teva's UK facility for 4 hours with banners reading 'Boycott Teva Pharma! No to Apartheid Drugs!' Part of growing European boycott campaign
Open sourceCEO confirms 10% of Israeli workforce called up to IDF reserves. Manufacturing continued despite conflict. Senior executive Hadar Mama reported fighting in Gaza while maintaining corporate duties
Open sourceConfirms Petah Tikva headquarters, 1901 founding, and position as world's largest generic drug maker with $16.5 billion revenue
Open sourceResearch shows Teva contributed approximately 10% of Israel's total industrial GDP (2003-2012), with employment multiplier of 5.53 and total economic multiplier of 1.98, making it a strategic pillar of the Israeli economy
Open sourceResearch on Teva's role in exploiting captive Palestinian pharmaceutical market under Paris Protocol. Historical involvement in settlement industrial zones including Barkan and Har Hotzvim
Open sourceUpdates & Milestones
- Restructuring Period
Major workforce reductions and debt restructuring amid industry challenges
- Actavis Acquisition
Acquires Actavis Generics for $40.5 billion, becoming world's largest generic drugmaker
- NASDAQ Listing
Becomes first Israeli company listed on NASDAQ
- Modern Teva Formed
Three Israeli pharmaceutical companies merge into Teva Pharmaceutical Industries
- Company Founded
Established in Jerusalem as wholesale drug distribution business